Allogene Therapeutics, Inc. (ALLO)

NASDAQ: ALLO · IEX Real-Time Price · USD

2.855

-0.185 (-6.09%)

At close: Apr 25, 2024, 4:00 PM

2.880

+0.025 (0.88%)

After-hours: Apr 25, 2024, 7:59 PM EDT

Allogene Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-327.27	-340.41	-182.05	-316.38	-184.59	-211.51
Depreciation & Amortization	14.2	14.3	10.45	7.44	4.42	1.05
Share-Based Compensation	65.95	83.6	80.82	65.26	46.06	18.57
Other Operating Activities	9.38	22	-94.03	128.59	-3.24	147.24
Operating Cash Flow	-237.73	-220.52	-184.81	-115.09	-137.35	-44.65
Capital Expenditures	-1.52	-5.19	-21.45	-65.96	-50.79	-3.23
Acquisitions	0	0	0	0	0	-2.1
Change in Investments	164.81	111.35	185.1	-439.17	214.88	-627.47
Investing Cash Flow	163.29	106.16	163.66	-505.12	164.08	-632.8
Share Issuance / Repurchase	95.7	2.95	11.96	633.59	58.96	355.06
Debt Issued / Paid	0	0	0	0	0	116.84
Other Financing Activities	-	-	-	-	-	299.28
Financing Cash Flow	95.7	2.95	11.96	633.59	58.96	771.18
Net Cash Flow	21.25	-111.41	-9.19	13.38	85.69	93.73
Free Cash Flow	-239.25	-225.71	-206.26	-181.05	-188.14	-47.89
Free Cash Flow Margin	-251841.05%	-144685.90%	-180.79%	-	-	-
Free Cash Flow Per Share	-1.52	-1.58	-1.52	-1.50	-1.86	-1.65

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).